Out of an abundance of caution, Pima County is following guidance from the Centers for Disease…
A new $1.9 million grant at the University of Arizona Steele Children’s Research Center will help researchers discover ways to prevent a deadly disease that affects thousands of premature infants annually. Necrotizing Enterocolitis (NEC), an inflammatory gastrointestinal disease, is one of the leading causes of illness and death among premature infants, affecting about 9,000 in the United States each year.
“We want to create the first test that will accurately predict if a premature baby may be susceptible to NEC, so we can treat and prevent it from developing,” explained UA Steele Center researcher and associate professor, Melissa Halpern, PhD.
Dr. Halpern will lead the study; Fayez K. Ghishan, MD, professor and UA Steele Center director, will provide his expertise in intestinal microbiome analysis and development of small-intestine organoids from stem cells harvested from surgical specimens. The four-year grant is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).
“Once NEC develops, the infant will face serious GI problems, so our goal is to prevent it,” said Dr. Halpern.
Dr. Halpern knows from personal experience how devastating NEC can be. Her son, Ryan, was born eight weeks prematurely and developed the disorder.
“We were lucky,” said Dr. Halpern, who changed her research focus to NEC after her son’s birth. “Ryan’s NEC wasn’t severe enough to require surgery, but this was a wake-up call to a disease that is fairly common among preemies, but not well-known or understood.”
In severe cases of NEC, a premature infant’s inflamed intestines may tear or perforate, which enables bacteria to leak into the abdomen—potentially causing life-threatening sepsis. As a result, damaged intestines may have to surgically be removed. These children often face lifelong severe digestive problems.
This study expands Dr. Halpern’s earlier research that discovered changes in intestinal bile acid levels in neonatal rodents with NEC, compared to those that did not develop the disease. Bile acids (a normal component of digestion) are produced in the liver and transported to the intestine to break down fats for digestion. They easily can be measured in fecal material and early data suggest fluctuations in bile acid levels occur prior to clinical symptoms in premature infants who develop NEC. The new grant will study if these fluctuations can be utilized as the first predictive test for NEC.